

Press communication Lund, Sweden, 9 November 2022 This is a translation of the Swedish press release published 2022-11-09

## Invitation to Neola Medical's presentation of the Q3-report 2022

Neola Medical AB (publ) publishes the Q3-report 2022 tomorrow Thursday the 10th of November 2022 and invites to presentation at 11am CET (11.00), via video conference.

Neola Medical publishes the Q3-report tomorrow morning the 10th of November 2022 and invites to a combined report presentation and video conference at 11am CET (11.00). Sign up to the presentation by sending an e-mail to Anna Goffhé, CEO Assistant at <a href="mailto:anna.goffhe@neolamedical.com">anna.goffhe@neolamedical.com</a>. After sign-up you will receive an invitation with a link to the presentation, that will be on Microsoft Teams. You can also send questions in advance to the same e-mail address.

## For further information, contact

Hanna Sjöström, CEO Neola Medical, tel: 0760-10 71 16, e-mail: <a href="https://hanna.sjostrom@neolamedical.com">hanna.sjostrom@neolamedical.com</a> Christian Gyllenberg, CFO Neola Medical, tel: 0727-44 50 10, e-mail: <a href="https://cristian.gyllenberg@neolamedical.com">https://cristian.gyllenberg@neolamedical.com</a>

Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants' lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at <a href="www.neolamedical.com">www.neolamedical.com</a>. The company's Certified Adviser is FNCA Sweden AB.